Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 318Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Atripla

02 12Biktarvy

03 1Complera

04 1Complera /Eviplera

05 8Complera/Eviplera

06 14Descovy

07 20Genvoya

08 14Odefsey

09 5Prezista/Prezcobix/Rezolsta/Symtuza

10 7Revenue share - Symtuza

11 15Stribild

12 9Symtuza

13 9Truvada

PharmaCompass

01

arrow
ASCO GU
Not Confirmed

02

arrow
ASCO GU
Not Confirmed

03

Brand Name : Complera/Eviplera

Emtricitabine

arrow
ASCO GU
Not Confirmed

Brand Name : Complera/Eviplera

arrow
ASCO GU
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 269

2019 Revenue in Millions : 406

Growth (%) : -34

blank

04

arrow
ASCO GU
Not Confirmed

05

Brand Name : Biktarvy

Emtricitabine

arrow
ASCO GU
Not Confirmed

Brand Name : Biktarvy

arrow
ASCO GU
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 7,259

2019 Revenue in Millions : 4,738

Growth (%) : 53

blank

06

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
ASCO GU
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
ASCO GU
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,184

2019 Revenue in Millions : 2,110

Growth (%) : 4

blank

07

arrow
ASCO GU
Not Confirmed

08

arrow
ASCO GU
Not Confirmed

09

arrow
ASCO GU
Not Confirmed

10

arrow
ASCO GU
Not Confirmed